Details of the Drug

General Information of Drug (ID: DMBT3AI)

Drug Name

Belantamab mafodotin

Indication

Disease Entry	ICD 11	Status	REF
Multiple myeloma	2A83	Approved	[1]
------------------------------------------------------------------------------------

ATC Code

L01FX15: Belantamab mafodotin

L01FX: Other monoclonal antibodies and antibody drug conjugates

L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Antibody drug conjugate

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 4666 mgh/L [2]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 42 mg/L [2]
Absorption Tmax: The time to maximum plasma concentration (Tmax) is 0.78 h [2]
Clearance: The clearance of drug is 0.9 L/day [2]
Half-life: The concentration or amount of drug in body reduced by one-half in 12 days [2]
Metabolism: The drug is metabolized via oxidation and demethylation, however further data is not readily available [2]
Vd: The volume of distribution (Vd) of drug is 11 L [2]

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
B-cell maturation protein (TNFRSF17)	TTZ3P4W	TNR17_HUMAN	Not Available	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
2	FDA Approved Drug Products: Blenrep Belantamab Mafodotin-blmf Intravenous Injection